메뉴 건너뛰기




Volumn 7, Issue 2, 2014, Pages 274-281

Chronic Dipeptidyl Peptidase-4 Inhibition With Sitagliptin Is Associated With Sustained Protection Against Ischemic Left Ventricular Dysfunction in a Pilot Study of Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Author keywords

Coronary Disease; Diabetes Mellitus; Dipeptidyl Peptidase Iv Inhibitors; Echocardiography, Stress; Glucagon Like Peptide 1

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DOBUTAMINE; GLUCAGON LIKE PEPTIDE 1; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN;

EID: 84900410339     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.113.000785     Document Type: Article
Times cited : (58)

References (30)
  • 1
    • 78649686908 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review
    • Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab. 2011;13:7-18.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 7-18
    • Deacon, C.F.1
  • 2
    • 77951168113 scopus 로고    scopus 로고
    • Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice
    • Sauvé M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, Drucker DJ. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes. 2010;59:1063-1073.
    • (2010) Diabetes , vol.59 , pp. 1063-1073
    • Sauvé, M.1    Ban, K.2    Momen, M.A.3    Zhou, Y.Q.4    Henkelman, R.M.5    Husain, M.6    Drucker, D.J.7
  • 3
    • 77951812608 scopus 로고    scopus 로고
    • The myocardial infarct size-limiting effect of sitagliptin is pka-dependent, whereas the protective effect of pioglitazone is partially dependent on pka
    • Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol. 2010;298:H1454-H1465.
    • (2010) Am J Physiol Heart Circ Physiol , vol.298
    • Ye, Y.1    Keyes, K.T.2    Zhang, C.3    Perez-Polo, J.R.4    Lin, Y.5    Birnbaum, Y.6
  • 4
    • 79959966874 scopus 로고    scopus 로고
    • Pre-treatment with a dpp-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats
    • Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther. 2011;25:13-20.
    • (2011) Cardiovasc Drugs Ther , vol.25 , pp. 13-20
    • Huisamen, B.1    Genis, A.2    Marais, E.3    Lochner, A.4
  • 6
    • 84872424922 scopus 로고    scopus 로고
    • An emerging role of dipeptidyl peptidase 4 (dpp4) beyond glucose control: Potential implications in cardiovascular disease
    • Zhong J, Rao X, Rajagopalan S. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis. 2013;226:305-314.
    • (2013) Atherosclerosis , vol.226 , pp. 305-314
    • Zhong, J.1    Rao, X.2    Rajagopalan, S.3
  • 7
    • 43249089631 scopus 로고    scopus 로고
    • Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
    • Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340-2350.
    • (2008) Circulation , vol.117 , pp. 2340-2350
    • Ban, K.1    Noyan-Ashraf, M.H.2    Hoefer, J.3    Bolz, S.S.4    Drucker, D.J.5    Husain, M.6
  • 8
    • 77951934948 scopus 로고    scopus 로고
    • Dpp-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease
    • Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging. 2010;3:195-201.
    • (2010) Circ Cardiovasc Imaging , vol.3 , pp. 195-201
    • Read, P.A.1    Khan, F.Z.2    Heck, P.M.3    Hoole, S.P.4    Dutka, D.P.5
  • 9
    • 0142219954 scopus 로고    scopus 로고
    • Strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function
    • Pellerin D, Sharma R, Elliott P, Veyrat C. Tissue Doppler, strain, and strain rate echocardiography for the assessment of left and right systolic ventricular function. Heart. 2003;89(Suppl 3):iii9-iii17.
    • (2003) Heart , vol.89 , Issue.SUPPL. 3
    • Pellerin, D.1    Sharma, R.2    Elliott, P.3    Veyrat, C.4    Doppler, T.5
  • 10
    • 0041474935 scopus 로고    scopus 로고
    • Myocardial doppler in stress echocardiography (mydise) study investigators. Non-invasive diagnosis of coronary artery disease by quantitative stress echocardiography: Optimal diagnostic models using off-line tissue doppler in the mydise study
    • Madler CF, Payne N, Wilkenshoff U, Cohen A, Derumeaux GA, Piérard LA, Engvall J, Brodin LA, Sutherland GR, Fraser AG; Myocardial Doppler in Stress Echocardiography (MYDISE) Study Investigators. Non-invasive diagnosis of coronary artery disease by quantitative stress echocardiography: optimal diagnostic models using off-line tissue Doppler in the MYDISE study. Eur Heart J. 2003;24:1584-1594.
    • (2003) Eur Heart J , vol.24 , pp. 1584-1594
    • Madler, C.F.1    Payne, N.2    Wilkenshoff, U.3    Cohen, A.4    Derumeaux, G.A.5    Piérard, L.A.6    Engvall, J.7    Brodin, L.A.8    Sutherland, G.R.9    Fraser, A.G.10
  • 15
    • 33644682164 scopus 로고    scopus 로고
    • Initial experience with glp-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure
    • Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res. 2004;1:40-43.
    • (2004) Diab Vasc Dis Res , vol.1 , pp. 40-43
    • Thrainsdottir, I.1    Malmberg, K.2    Olsson, A.3    Gutniak, M.4    Rydén, L.5
  • 16
    • 33845293219 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
    • Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12:694-699.
    • (2006) J Card Fail , vol.12 , pp. 694-699
    • Sokos, G.G.1    Nikolaidis, L.A.2    Mankad, S.3    Elahi, D.4    Shannon, R.P.5
  • 17
    • 1442311383 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
    • Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962-965.
    • (2004) Circulation , vol.109 , pp. 962-965
    • Nikolaidis, L.A.1    Mankad, S.2    Sokos, G.G.3    Miske, G.4    Shah, A.5    Elahi, D.6    Shannon, R.P.7
  • 20
    • 51749088973 scopus 로고    scopus 로고
    • Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes
    • Mussig K, Oncu A, Lindauer P, Heininger A, Aebert H, Unertl K, Ziemer G, Haring HU, Holst JJ, Gallwitz B. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am J Cardiol. 2008;102:646-647.
    • (2008) Am J Cardiol , vol.102 , pp. 646-647
    • Mussig, K.1    Oncu, A.2    Lindauer, P.3    Heininger, A.4    Aebert, H.5    Unertl, K.6    Ziemer, G.7    Haring, H.U.8    Holst, J.J.9    Gallwitz, B.10
  • 21
    • 84857111888 scopus 로고    scopus 로고
    • Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
    • Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart. 2012;98:408-413.
    • (2012) Heart , vol.98 , pp. 408-413
    • Read, P.A.1    Khan, F.Z.2    Dutka, D.P.3
  • 22
    • 84860390563 scopus 로고    scopus 로고
    • A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
    • Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE, Dutka DP. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv. 2011;4:266-272.
    • (2011) Circ Cardiovasc Interv , vol.4 , pp. 266-272
    • Read, P.A.1    Hoole, S.P.2    White, P.A.3    Khan, F.Z.4    O'Sullivan, M.5    West, N.E.6    Dutka, D.P.7
  • 23
    • 80052072913 scopus 로고    scopus 로고
    • Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: Evidence for improving cardiac metabolic efficiency
    • Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR, Harpel MR, Willette RN, Lepore JJ, Jucker BM. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One. 2011;6:e23570.
    • (2011) PLoS One , vol.6
    • Bao, W.1    Aravindhan, K.2    Alsaid, H.3    Chendrimada, T.4    Szapacs, M.5    Citerone, D.R.6    Harpel, M.R.7    Willette, R.N.8    Lepore, J.J.9    Jucker, B.M.10
  • 24
    • 0037629509 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
    • Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikstrom G, Gutniak M. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides. 2003;24:569-578.
    • (2003) Peptides , vol.24 , pp. 569-578
    • Kavianipour, M.1    Ehlers, M.R.2    Malmberg, K.3    Ronquist, G.4    Ryden, L.5    Wikstrom, G.6    Gutniak, M.7
  • 25
    • 0019543906 scopus 로고
    • Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart
    • Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis. 1981;23:321-336.
    • (1981) Prog Cardiovasc Dis , vol.23 , pp. 321-336
    • Liedtke, A.J.1
  • 29
    • 77958195997 scopus 로고    scopus 로고
    • The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: Possible role of stromal-derived factor-1alpha
    • Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, Agostini C, Tiengo A, Avogaro A. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care. 2010;33:1607-1609.
    • (2010) Diabetes Care , vol.33 , pp. 1607-1609
    • Fadini, G.P.1    Boscaro, E.2    Albiero, M.3    Menegazzo, L.4    Frison, V.5    De Kreutzenberg, S.6    Agostini, C.7    Tiengo, A.8    Avogaro, A.9
  • 30
    • 84876780409 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes
    • Matsubara J, Sugiyama S, Akiyama E, Iwashita S, Kurokawa H, Ohba K, Maeda H, Fujisue K, Yamamoto E, Kaikita K, Hokimoto S, Jinnouchi H, Ogawa H. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77:1337-1344.
    • (2013) Circ J , vol.77 , pp. 1337-1344
    • Matsubara, J.1    Sugiyama, S.2    Akiyama, E.3    Iwashita, S.4    Kurokawa, H.5    Ohba, K.6    Maeda, H.7    Fujisue, K.8    Yamamoto, E.9    Kaikita, K.10    Hokimoto, S.11    Jinnouchi, H.12    Ogawa, H.13


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.